Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T13:25:59.857Z.
Calculation as of: 2026-10-06T13:25:59.857Z.
Quote observation: 2026-10-05T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 1c5d1a4dd2ed90e95308857a7b7df8ea0860f9bef9a655807fa9e02aea5f37e0
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Cellectar Biosciences, Inc.
Market Cap
$13.34M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$14.28M
EV/EBITDA Ratio
N/A
TTM Avg
116.01x
3Y Avg
116.01x
5Y Avg
116.01x
Market Cap
$11.95M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$11.94M
EV/EBITDA Ratio
N/A
TTM Avg
133.45x
3Y Avg
63.52x
5Y Avg
51.85x
Market Cap
$15.20M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cellectar Biosciences, Inc. (CLRB) | $13.34M | N/A | N/A | N/A | N/A |
| Vyome Holdings, Inc. (HIND)vs › | $13.55M | N/A | N/A | N/A | N/A |
| IN8bio, Inc. (INAB)vs › | $13.62M | N/A | N/A | N/A | N/A |
| Dare Bioscience, Inc. (DARE)vs › | $12.63M | N/A | N/A | N/A | N/A |
| Cytosorbents Corporation (CTSO)vs › | $12.46M | N/A | N/A | N/A | N/A |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $14.28M | N/A | 116.01x | 116.01x | 116.01x |
| CytoMed Therapeutics Limited (GDTC)vs › | $11.95M | N/A | N/A | N/A | N/A |
| IRIDEX Corporation (IRIX)vs › | $11.94M | N/A | 133.45x | 63.52x | 51.85x |
| Karyopharm Therapeutics Inc. (KPTI)vs › | $15.20M | N/A | N/A | N/A | N/A |
| Pasithea Therapeutics Corp. (KTTA)vs › | $15.20M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
